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Abstract The role of PMNs (neutrophils) in corneal
herpes was studied using an in vitro system. Human
corneal cells (HCE) and macrophages (THP-1) infected
with HSV-1 or treated with virus components (DNA or virus
immune complexes) released chemokines, which attracted
PMNs. Highly reactive oxygen species were detected in
PMNs. PMNs inhibited HSV when overlaid onto infected
HCE cells (50:1). PMNs incubated with the supernatants of
HCE cells treated with virus components released H2O2 and
myeloperoxidase. These inhibited virus growth. PMNs
released NO and MIG, which may differentiate CD4 T cells
to Th1. PMNs participate in innate immune responses, limit
virus growth, and initiate immunopathology.
The host responses to corneal herpes simplex virus type-1
(HSV-1) infection elicit vigorous inﬂammation and neo-
vascularization [1–3]. When HSV-1 is inoculated into the
mouse cornea, infectious virus disappears from the afﬂicted
lesions 4 to 5 days postinfection (PI) [4, 5]. How HSV-1 is
eliminated and what triggers subsequent immunopatho-
logical lesions is still not well understood. Previously, we
reported that human corneas contain a high copy number of
HSV DNA and deposited HSV immune complexes
(HSV-IC) [6]. Human corneal epithelial cells (HCE) and
human corneal ﬁbroblasts have been shown to release IL-6
via TLR-3 and -9 [7]. These viral components cause new
vessels to be leaky so that leukocytes can pass through
them in the afﬂicted cornea [8]. Here, we attempt to
identify chemotactic factors released from corneal cells and
macrophages treated with virus components and to study
factors released from activated PMNs, which may inhibit
virus growth during herpetic corneal infection.
Human corneal epithelial cells (HCEs) were propagated
in 6-, 24- or 96-well plates with MEM supplemented
with 10 % fetal bovine serum, essential amino acids and
antibiotics. THP-1 cells, a human monocyte-macrophage
cell line, were cultured in 6- or 24-well plates with
1.0-2.5 9 10
6 cells/well with RPMI1640 supplemented
with 10 % fetal bovine serum, antibiotics and PMA (20 ng/
ml). Puriﬁed CD16
? human PMNs (1 9 10
8 cells) in
RPMI 1640 were purchased from All Cells (Emeryville,
CA). Puriﬁed human peripheral blood CD4 T cells (HPBT)
were purchased from Lonza (Lonza, Walkersville, MD)
and cultured in LCM-3 medium supplemented with PHA
(1 lg/ml) and rIL-2 (10 ng/ml). HSV-1, Mckrae (5 9 10
7
PFU/ml) and the MP strain (5 9 10
6 PFU/ml) were used.
They were partially puriﬁed by centrifugation at 14,000
rpm for 90 min in a Sorvall SS34 rotor. Some of the par-
tially puriﬁed virus was further puriﬁed by sucrose density
gradient centrifugation (10–60 % w/v) using a Beckman
SW28 swing rotor for 1 h at 11,500 rpm. Viral DNA was
isolated from the puriﬁed virus using a QIAamp UltraSens
Virus Kit (QIAGEN, Valencia, CA). Herring sperm DNA
purchased from Roche Diagnostics (Indianapolis, IN) was
used as a DNA control. To make HSV-1-anti-HSV IgG
K. Hayashi (&)  L. C. Hooper  J. J. Hooks
Immunology and Virology Section, Laboratory of Immunology,
National Eye Institute, NIH, Bethesda, MD 20892, USA
e-mail: kozaburo@yc4.so-net.ne.jp
T. Okuno
Department of Microbiology, Hyogo College of Medicine,
Hyogo, Japan
Y. Takada
Biological Imaging Core, NEI, NIH, Bethesda, USA
123
Arch Virol (2012) 157:1377–1381
DOI 10.1007/s00705-012-1306-yimmune complexes (HSV-ICs), puriﬁed HSV-1 (Mckrae
and MP strains) were mixed with 5.0 % human c-globulin
(human c-globulin Cohn fraction II, III: neutralizing titer
1:640; Sigma, Milwaukee, WI) overnight at 4 C and then
centrifuged, and the pellet was washed twice with PBS.
HSV-ICs were not infectious when assayed on Vero cell
monolayers.
Kinetic and viral-dose-dependent (from m.o.i. = 0.1 to
100.0) release of chemokines (IL-8, Gro-a and a cytokine,
GM-CSF, from HSV-treated HCE monolayers) were
assayed by ELISA (R&D Systems, Minneapolis, MN).
Induction of chemotaxis of PMNs by these supernatants,
recombinant IL-8, rGro-a and rGM-CSF and these
recombinant proteins plus the corresponding antibodies
(R&D Systems) were assayed on 96-well HTS chemotaxis
chamber plates (5.0-lm pore size. Corning Life Science,
MA) using the alamarBlue (AB) bio-staining method
(Invitrogen). Rabbit IgG was used as an antibody control.
Wells with serum-free RPMI 1640 served as controls.
PMNs (5 9 10
5 cells/well) were added to the upper inserts
and incubated at 37 C for 2 hours, then the inserts were
removed, and 10 ll of AB was added to the bottom wells.
After incubation for 18 hours, the number of PMNs in the
bottom wells was estimated by absorbance at 570 nm with
600 nm as a reference wavelength. A standard curve was
generated with a serial twofold dilution from 1 9 10
6 to
1.25 9 10
5 of PMNs.
The activated state of PMNs mixed with supernatants
obtained from HCE and/or THP-1 cells treated with HSV-1
components was observed under a ﬂuorescence microscope
after incubation for 30 minutes with 10 lMa m i n o p h e n y l
ﬂuorescein (APF, Assay Designs, Ann Arbor, MI) [9].
Release of type 1 interferons, TNF-a and MIG from PMNs
treated with recombinant chemokines and rGM-CSF,
supernatants of HCE or THP-1 cells treated with viral
components was assayed by ELISA (interferon-a [PBL
Interferon Source, Piscataway, NJ], interferon-b [FUJIRE-
BIO, Tokyo] and TNF-a [R&D Systems]). For the assay of
MIG, equal numbers of PMNs and peripheral CD4 T cells
were mixed with the supernatants obtained from virus-
component-treated HCE cells. After incubation for 24 hours,
supernatantswere assayedbyELISA(R&D Systems).PMNs
(1 9 10
6 cells/well) were mixed with supernatants of HCE
and/or THP-1 cells treated with HSV-1 components, and the
amount of H2O2 and myeloperoxidase (MPO) released from
the PMNs was measured using a Cayman H2O2 assay kit
(Cayman Chemical Co. Ann Arbor, MI) and a human MPO
enzyme immunometric assay kit (Assay Design, Ann Arbor,
MI). NO release from the treated PMNs was assayed using a
total NO/Nitrite/Nitrate assay kit (R&D Systems), which
converts the nitrate into nitrite using nitrate reductase.
Endogenous nitrite concentrations were subtracted from the
values obtained after nitrate reductase treatment.
To measure the viral inhibitory activities of H2O2 and
MPO, HSV-1 (100 PFU/0.1 ml of Mckrae and/or MP
strain) was mixed with serially twofold diluted H2O2
(3,500 to 438 ng/ml) or MPO (25.0 to 3.12 ng/ml) for one
hour at 37 C. After the incubation, the virus titer was
estimated. Vero cells pretreated with 3,500 to 438 ng/ml of
H2O2 were used as a control for the cytotoxicity of H2O2.
Experiments were repeated three times, and the results
were statistically analyzed by Student’s t-test.
After HSV-1 infection, release of IL-8, Gro-a and GM-
CSF from HCE cells increased as early as 2 hours PI. IL-8
and Gro-a levels plateaued at 8 hours PI, from 0 to
257.8 ± 38.5 pg/ml and from 0 to 23.0 ± 5.8 pg/ml,
respectively. The amount of GM-CSF released was 83.0 ±
11.4 pg/ml at 2 hours PI and reached 453.0 ± 56.2 pg/ml
at 10 hours PI. Uninfected HCE did not release IL-8 or
Gro-a, while a small amount of GM-CSF (73.5 ± 1.40)
was released spontaneously.
Supernatants obtained from cells treated with the MP
strain and its components were more potent in their ability
to attract PMNs than those obtained from cells treated with
the Mckrae strain, and therefore, the results obtained
using the MP strain are described. Supernatants obtained
from HCE and THP-1 cells infected with the MP strain
(m.o.i. = 1.0) and/or treated with its components attracted
more PMNs than the control medium except, supernatant
obtained from THP-1 cells infected with the live MP strain.
When the parametric number of chemoattracted PMNs
with supernatants of MP-infected, MP DNA-transfected
and MP-IC-treated HCE and /or THP-1 cells was set to
100, supernatants obtained from untreated HCE and THP-1
cells or cells treated with normal rabbit IgG were 0.5 to 4
(p\0.01). When supernatants were mixed with anti-IL-8
and anti-GM-CSF, the chemotactic activity was reduced
from 48 to 0.5 (p\0.05). When PMNs were incubated
with the Mckrae and/or MP strain, cell-free and cell-
associated infectious viruses became undetectable at
48 hours PI. When PMNs were overlaid onto HSV-infected
HCE cell monolayers (m.o.i. = 10.0 for Mckrae and 1.0
for MP) with a PMN:HCE ratio of 50:1 for 24 hours, virus
growth was suppressed; the infectious titer of the Mckrae
strain was reduced on average from 1.0 9 10
5 PFU to
2.3 9 10
2 PFU/ml and that of the MP strain from 4.0 9
10
4 PFU to 2.0 9 10
2 PFU/ml. Supernatants of PMNs
mixed with supernatants obtained from Mckrae- or MP-
infected or virus-component-treated HCE or THP-1 cells
inhibited HSV growth, although the inhibitory activities
were weak, ranging from 1/3 to 1/8 of HSV growth com-
pared to cells treated with control supernatant of PMNs.
TNF-a was released, from 8 to 25 pg/ml, from PMNs
incubated with supernatants of HSV-infected, HSV-DNA-
and MP-IC-treated HCE cells and 80 pg/ml from
MP-IC-treated THP-1 cells. However, TNF-a was not
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123inhibitory to the virus at these concentrations. Interferon-a,
-b and -c were not released from PMNs mixed with treated
HCE and THP-1 cell supernatants. The concentration of
MIG released from PMNs plus peripheral CD4 T cells
mixed with supernatants of HCE cells infected with Mck-
rae, transfected with Mckrae DNA, or treated with Mckrae
IC ranged from 2,500 to 3,000 pg/ml. HCE cells trans-
fected with herring DNA did not induce MIG in PMNs and
peripheral CD4 T cells. H2O2 was released from PMNs
mixed with the supernatants of HCE cells infected with
Mckrae and MP, transfected with MP DNA and treated
with HSV-IC (Fig. 1a). Release of H2O2 from PMNs was
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Fig. 1 (a) Supernatants of HCE cells that had been infected with the
Mckrae or MP strain or treated with virus components were mixed
with PMNs at 37 C for 24 hours. The amount of H2O2 in the
supernatants was measured using a Cayman H2O2 assay kit.
Supernatants obtained from Mckrae or MP-infected, MP-DNA
and HSV-IC-treated PMNs released more than 4,000 ng H2O2/ml.
(b and c) The Mckrae (b) and MP (c) strains were mixed with serially
twofold-diluted H2O2, incubated at 37 C for one hour, and then
added to the Vero cell monolayers. After adsorption for two hours, the
monolayers were washed with PBS and overlaid with complete
medium supplemented with 2 % human c-globulin (anti-HSV neu-
tralizing antibody titer = 1:640). Viral plaques were counted at
48 hours after inoculation. Untreated viruses served as controls.
Growth of both strains was clearly inhibited at an H2O2 concentration
above 876 ng/ml (p\0.01)
0
5
10
15
20
25
30
Mckrae Mck-DNA Mck-IC Control
n
g
/
m
l
HCE Treated with Virus Components
Cell (HCE+PMN) Associated Myeloperoxidase 
Inhibition of HSV (Mckrae strain)growth 
0
2
4
6
8
10
12
14
16
control 3.12ng/ml 6.25ng/ml 12.5ng/ml 25.0ng/ml
Myeloperoxidase 
P
F
U
(
X
1
0
3
)
/
m
l
Inhibition of HSV(MPstrain)
0
2
4
6
8
10
12
14
16
control 3.12ng/ml 6.25ng/ml 12.5ng/ml 25.0ng/ml
Myeloperoxidase
P
F
U
(
X
1
0
2
)
/
m
l
with  Myeloperoxidase 
with Myeloperoxidase
a
b
c
Fig. 2 (a) MPO was assayed using a human MPO immunometric
assay kit (Assay Design). MPO was constitutively cell-associated in
PMNs, but slightly more MPO was detectable when PMNs were
mixed with the supernatants of virus-treated HCE cells. (b and c)
When Mckrae (b) and MP (c) strain of HSV were treated with MPO
from 3.12 to 25.0 ng/ml at 37 C for one hour, growth of both strains
was inhibited (Mckrae at 25.0 ng/ml and MP strain, p\0.01)
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123also seen when supernatants of THP-1 cells were infected
with Mckrae, transfected with HSV DNA, or treated with
MP-IC. Growth of the Mckrae and MP strains was inhib-
ited in a dose-dependent manner by H2O2 (Fig. 1b and c).
Control Vero cells pretreated with H2O2 (from 438 ng to
3,000 ng/ml) supported Mckrae strain growth similar to
untreated Vero cells. Therefore, H2O2 inhibited HSV-1
directly. Slightly, though not signiﬁcantly, more MPO was
detectable in PMNs when they were treated with the
supernatants of virus-treated HCE cells (Fig. 2a). When
HSV-1 was mixed with MPO at 37 C for one hour, the
virus titers decreased with increasing concentrations of
MPO (p\0.01, Fig. 2b and c). PMNs released from
280 lmol to 430 lmol/ml of NO into the supernatant when
they were mixed with HCE or THP-1 cell supernatants
treated with HSVDNA and HSV-IC (Fig. 3). These levels
of NO were signiﬁcantly higher than those obtained from
the untreated HCE supernatant control (p\0.01). NO does
not directly inhibit viral growth at the range of concen-
trations obtained from treated HCE.
In the local chemokine milieu, PMNs are activated and
held at the afﬂicted site [10]. Following murine corneal
inoculation, HSV-1 was cleared after initial exponential
growth for 4–5 days [4]. This elimination of active virus
growth may be explained at least in part by the innate
immune system and the accumulated PMNs [4–6, 11]. In
our in vitro model system, PMNs were activated, as evi-
denced by the production of hROS [9], inhibited HSV
spread, and did not support HSV growth. These data agree
with the previous reports indicating that PMNs initiate
virus clearance [4–6]. PMNs release various mediators
such as TNF-a, H2O2, MPO and NO. TNF-a has been
suggested to inhibit the virus [11, 12], but in our study, it
was not directly inhibitory. H2O2 and MPO inhibited virus
growth within the range of concentrations obtained from
the treated and activated PMNs. In addition to H2O2 and/or
MPO, phagocytosis by PMNs was one of the major
inhibitory factors, because at this early period of infection,
the effects of anti-HSV antibody and T-cell-mediated
immunity were only at the very beginning. Corneal herpes
occurs most commonly as a reactivated virus infection, and
therefore PMNs can recognize antibody-coated virus par-
ticles and infected cells with Fc receptor and inhibit virus
growth and spread by ADCC [13]. In mice, the chronic
phase of infection follows with strong stromal opacity and
neovascularization. These are pathognomonic and charac-
teristic of HSK. In these situations, accumulation of viral
DNA and deposition of HSV-IC are well documented [6].
PMNs inﬁltrate the lesions and cause dense corneal haze. A
previous report suggested the importance of NO in the
defense against corneal herpes [14]. Interestingly, a low
concentration of NO is one of the contributing factors for
the differentiation of naı ¨ve peripheral CD4 T cells into Th1
T cells [15]. Nitrate ranging from 280-430 l/ml was
detected in the supernatant of PMNs mixed with HCE
supernatant treated with virus components (Fig. 3). This
range of NO concentration may induce naı ¨ve CD4 T cells
to differentiate to Th1 cells [15]. We added peripheral CD4
T cells to the supernatants obtained from the treated HCE
cells plus PMN. However the amount of IFN-c released
from CD4 T cells mixed with the PMN supernatant
obtained from untreated HCE cells was not signiﬁcantly
different from that obtained from CD4T cells treated with
HCE cells plus PMNs. Neutrophils recruited to the site are
induced to produce other factors such as MIG, which is
also known to induce and accumulate CD4
? Th1 cells [16].
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Fig. 3 Supernatants obtained from PMNs that had been mixed with
HCE supernatants treated with HSV components was deproteinized
using 10,000-MW-cutoff ﬁlters (R&D systems), and the total nitrite
oxide (NO) in the samples was measured using an NO/Nitrite/Nitrate
assay kit (R&D). The amount of NO in the PMN supernatants mixed
with HCE supernatants treated with HSV DNA and HSV-IC was
signiﬁcantly higher, ranging from 280 to 430 lmol/ml, than in those
from untreated HCE cells or the herring DNA control (p\0.01)
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123When PMNs and CD4 T cells were mixed and incubated
with HCE supernatants treated with HSV components,
2,500 to 3,000 pg/ml of MIG was released. These local
environments may contribute to peripheral naı ¨ve CD4 T
cell differentiation to Th1, but further study of this problem
has to be done in the future.
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